Next Phase Newsletter

A Global High-tech companies makes equity investments and is seeking strategic partnerships with early-stage companies. The firm’s equity investments are typically of $1-3 million although the firm is very capable of making allocation outside this range as well.

Within the life science space the firm focuses on the backend of connected healthcare, with the goal of using communications technology to enable a network of care, with the patient at the center using devices to share information with healthcare professionals and with family members and other careers. The firm is therefore investing primarily in medical devices and lab equipment that transmit information wirelessly, particularly those that bring innovation to hospitals and clinics. The firm generally does not invest in equipment used in very complex wet chemistry (such as assay equipment) but is otherwise open to considering any innovations involving transmitting data from devices in the healthcare and biotech R&D equipment field. The firm is also open to healthcare IT opportunities. In addition to wireless data transmission, the firm’s technological focus in the healthcare field includes very small vital sensors and variable power technologies that can deliver increased battery life. The firm prefers to invest in technologies that are at commercialization stage or close to approval, but earlier stage opportunities may be of interest. While the firm will consider any indication, elder care is of particular interest, and the firm also has programs in the consumer health, wellness and beauty fields.

The firm only invests in companies that are interested in a long-term strategic partnership with the firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a global science-based company active in health, nutrition and materials is looking The firm makes equity investments into seed and venture stage companies. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

The firm is looking for companies in the intersection of Life and Materials Sciences. These includes companies developing devices and materials targeting indications of cardiovascular, orthopedics, ophthalmology, dental, drug delivery and next generation cellular therapy. The firm is also interested in companies in the Agbio and nutraceutical spaces. While the firm has invested in companies all the way from seed to 3-month pre-IPO, they generally invest into companies that do not yet have a product on the market.

The firm highly values experience in a firm’s management team and generally looks to take a board seeks and play an active role in its portfolio companies. The firm is looking for companies that are in cooperation/alignment with the parent business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of subsidiary of a US healthcare provider has closed its third fund at $225 million in 2012.The firm makes equity investments into early-stage companies of approximately $3 million to $10 million initially with additional capital reserved for follow on financings, and generally it can invest $4 million to $15 million over a life cycle. The firm seeks to invest in companies in Series A & B financing rounds, but it is open to consider companies in other stages of development. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US.

The firm is currently looking for new opportunities in the Medical Devices, Diagnostics, Healthcare IT and Healthcare Services spaces. The firm considers all classes of medical devices and focuses on companies in the clinical stage. However, the firm will also considers products that are on the market. The firm is generally opportunistic in terms of indication.

The firm primarily invests in pre-revenue private companies. The firm looks to invest in companies with a strong management team who can demonstrate relevant experience, depth and capability to build and scale the business and attract customers Ascension Ventures typically requests a Board seat or Board observation rights for each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a global science-based company active in health, nutrition and materials is looking The firm makes equity investments into seed and venture stage companies. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

The firm is looking for companies in the intersection of Life and Materials Sciences. These includes companies developing devices and materials targeting indications of cardiovascular, orthopedics, ophthalmology, dental, drug delivery and next generation cellular therapy. The firm is also interested in companies in the Agbio and nutraceutical spaces. While the firm has invested in companies all the way from seed to 3-month pre-IPO, they generally invest into companies that do not yet have a product on the market.

The firm highly values experience in a firm’s management team and generally looks to take a board seeks and play an active role in its portfolio companies. The firm is looking for companies that are in cooperation/alignment with the parent business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A biotechnology-focused equity hedge fund based in Western US is looking to invest in therapeutics space. The investment size can vary greatly and the fund is very flexible depending on each company’s needs. The fund is geographically agnostic and looks to invest globally.

The firm is highly interested in biotech therapeutics. The fund is extremely opportunistic in terms of subsectors and indications and will consider companies at all stages of development. The fund recently invested in a European-based company developing small molecule therapeutics for CNS diseases and a US-based company developing therapeutics for oncology.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The fund will require either a board seat or observer status.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital company with offices all around the globe is currently looking to make equity investments generally ranging from $5 to $25 million. The firm has no set number of investments it plans to make over the next 6-9 months but is actively reviewing companies for investment. The firm is willing to pursue opportunities located globally.

The firm is looking for companies in sectors of Biotechnology Therapeutics, Diagnostics, and Nutrition/Food. The firm is most interested in areas of brain health, GI (gastro intestinal), metabolic disorders and aging. The firm typically looks for early human clinical data and focused on compounds (both small molecules and biologics) with a strong safety profile that are suitable for chronic use, along with strong IP protection and a scientific rationale for their effect.

The is looking for management teams with domain expertise and a strong track record and generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The Corporate Venture arm of a Hi-Tech Company current manages a total of $850 million in assets, and is looking to make equity investments ranging from $2-$5 million with the ability to allocate up to $10 million generally in series A-C rounds. The majority of fund’s investment have been throughout the United States although they have and are willing to invest internationally as well. The fund is actively reviewing new opportunities can could make 3-4 investments over the next year.

The Fund is currently interested in sectors of Medical Devices, Diagnostics and Healthcare IT that increase connectivity in the healthcare ecosystem. The fund is particularly interest in verticals of Health and Wellness, Chronic Disease Care, Aging in Place, Telemedicine, Genomics, Patient Monitoring, Clinical Trails Management, Mobile Software Healthcare IT Applications, and Electronic Medical Records Management. The fund is willing to invest in devices with 510k pathways however the fund is not currently considering highly invasive medical devices.

The Fund is looking for privately held companies with experienced management teams. The fund generally looks to take a board or observer seat following investment and is willing to both lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com